Telix Pharmaceuticals has reported a first-half loss of $4.8 million, despite a significant increase in revenue. The loss follows the company’s acquisition of a radio pharmacy network in the United States. Telix reaffirmed its revenue guidance, even as it navigates increased expenses. Telix Pharmaceuticals is a global biopharmaceutical company focused on the development of diagnostic and therapeutic products using molecularly targeted radiation. The company is dedicated to improving the lives of patients with cancer and other unmet medical needs.
Revenue for the six months ending in June climbed 63 per cent to $390.4 million, highlighting strong sales performance. However, the company stated that the loss included $12.4 million in finance costs associated with a convertible bond issue, as well as costs related to the recent RLS acquisition. These factors significantly impacted the bottom line, overshadowing the revenue gains.
It was noted last month that the company’s shares experienced a decline after the US Securities and Exchange Commission (SEC) issued a subpoena. This subpoena sought information pertaining to disclosures related to the development of Telix’s prostate cancer therapies. The company is cooperating with the SEC to address any concerns.
Despite the current financial results and regulatory oversight, Telix maintains its revenue outlook, suggesting confidence in its core business and future growth prospects. The company’s strategic acquisitions and ongoing development of cancer therapies remain central to its long-term strategy.
